ARQT vs. QCOM

In the year-to-date period, ARQT achieves a 5.67% return, which is significantly higher than QCOM's -3.66% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and QUALCOMM Incorporated (QCOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ARQT Sharpe Ratio is 0.88, which is higher than the QCOM Sharpe Ratio of -0.14. The chart below compares the historical Sharpe Ratios of ARQT and QCOM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

ARQT has not paid dividends to shareholders, while QCOM's dividend yield for the trailing twelve months is around 2.31%.

The maximum ARQT drawdown since its inception was -95.02%, which is greater than QCOM's maximum drawdown of -86.75%. Use the drawdown chart below to compare losses from any high point for ARQT and QCOM. For additional features, visit the drawdowns tool.

Arcutis Biotherapeutics, Inc. (ARQT) and QUALCOMM Incorporated (QCOM) have volatilities of 23.90% and 22.87%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and QUALCOMM Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.